ASCLETIS-B (01672) has announced the successful completion of a placement involving a total of 69.256 million shares on February 10, 2026. The shares were priced at HK$12.18 per share, generating net proceeds of approximately HK$835 million. Approximately 90% of the funds are designated for the preparation, foundational work, and initiation of the global Phase III clinical trials for ASC30, an oral small-molecule GLP-1 receptor agonist intended for the treatment of obesity. The remaining 10% is allocated for working capital and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments